** Shares of drugmaker BioMarin Pharmaceutical BMRN.O rise 10.5% to $72.51 premarket
** Co, after market close on Wednesday, reported Q4 rev. of $747 mln, beating estimate of $713.4 mln, as per data compiled by LSEG
** Reported Q4 adj. profit of 92 cents per share vs estimate of 53 cents per share
** Forecast 2025 adj. profit in the range of $4.20 to $4.40 per share, above estimate of $3.26 per share
** Brokerage Evercore ISI says BMRN's Q4 results are "solid"; adds "it looks like investors may be willing to reward the company for solid execution after all. This was indeed an encouraging update on multiple fronts"
** Stock had fallen 31.8% in 2024
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。